Tauriga Sciences, Inc. Files Provisional U.S. Patent Application Covering its Pharmaceutical Grade Version of Tauri-Gum
March 18 2020 - 7:56AM
InvestorsHub NewsWire
Tauriga Sciences, Inc. Files
Provisional U.S. Patent Application Covering its Pharmaceutical
Grade Version of Tauri-Gum
The
Patent is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF
MANUFACTURING, AND METHODS OF TREATMENT”
NEW YORK, NY -- March 18, 2020 -- InvestorsHub NewsWire --
Tauriga Sciences, Inc. (OTCQB: TAUG)
(“Tauriga” or the “Company”), a revenue generating Company that
operates through the development, distribution, and licensing of
proprietary products as well as the evaluation of potential
acquisition opportunities and equity investments, today announced
that it has filed a Provisional U.S. Patent Application covering
its Pharmaceutical grade version of Tauri-Gum™. This patent
application, filed with the United States Patent & Trademark
Office (“U.S.P.T.O.”), is titled: “MEDICATED CBD COMPOSITIONS,
METHODS OF MANUFACTURING, AND METHODS OF TREATMENT.” The
Company’s proposed Pharmaceutical grade version of Tauri-Gum™ is
being developed for nausea regulation, intended specifically to
target: patients subjected to ongoing chemotherapy treatment(s)
(the “Indication”). The delivery system for this
Pharmaceutical product is an improved version of the existing
“Tauri-Gum™” chewing gum formulation based on continued research
and development.
The law-firm of Lowenstein Sandler assisted the Company in
constructing this important intellectual property application.
U.S. Provisional Patent Application No. 62/990,709
In other news, the Company continues to report strength in its
E-Commerce business. Most notably the average dollar amount,
of each individual transaction, has substantially increased over
past several days. The Company is on track to generate record
monthly E-Commerce revenue for the month of March 2020.
ABOUT TAURIGA SCIENCES INC.
Tauriga Sciences, Inc. (TAUG)
is a revenue generating Company that operates through the
development, distribution, and licensing of proprietary products as
well as the evaluation of potential acquisition opportunities. One
such opportunity on which the Company has acted, involves the
Company having entered into the cannabidiol (or “CBD”) infused
chewing gum product business, as more fully described above and in
prior press releases. This CBD infused chewing gum product
has been branded under the following name:
Tauri-Gum™. The Company is currently in production of
three distinct flavors of Tauri-Gum™: MINT, BLOOD ORANGE, and
POMEGRANATE. On December 6, 2019 the Company announced that
it completed the initial production run (thereby expanding its
existing product lines) with the introduction of a 25mg Vegan CBD
Isolate Infused vegan gummy (“gum drop”), branded under the name:
Tauri-Gummies™. Further, the Company continues to identify
and evaluate additional potential opportunities to generate
revenue, as well as shareholder value, and leverage its resources
and expertise to build a diversified and sustainable business
model. The Company has also announced the development of a
Cannabigerol (“CBG”) Isolate infused version of Tauri-Gum™.
The flavor that has been selected is Starfruit/Peach and each piece
of gum will contain 10mg of CBG Isolate / Each blister pack will
contain 80mg of CBG Isolate. Please visit our corporate
website at www.tauriga.com.
In addition - during 2019, the Company announced the official
launch of its E-Commerce site - as part of its Tauri-Gum™
commercialization strategy. This site can be accessed by
visiting the following URL address: www.taurigum.com
On January 13, 2020, the Company formed a wholly owned
subsidiary called: Tauriga Pharma Corp. This subsidiary is
focused on the development of a Pharmaceutical grade version of
Tauri-Gum™, for nausea regulation (specifically designed to help
patients that are subjected to ongoing chemotherapy
treatment(s)). On March 18, 2020, the Company announced that
it filed a provisional U.S. patent application covering its
pharmaceutical grade version of Tauri-Gum™. The Patent, filed
with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS
OF MANUFACTURING, AND METHODS OF TREATMENT”.
The Company has established corporate offices in both New York
City (USA) and Barcelona (Spain) and operates a full time
E-Commerce fulfillment center located in LaGrangeville, New
York.
DISCLAIMER -- Forward-Looking Statements
This press release contains certain “forward-looking statements”
as defined by the Private Securities Litigation Reform Act of 1995
which represent management’s beliefs and assumptions concerning
future events. These forward-looking statements are often indicated
by using words such as “may,” “will,” “expects,” “anticipates,”
believes, “hopes,” “believes,” or plans, and may include statements
regarding corporate objectives as well as the attainment of certain
corporate goals and milestones. Forward-looking statements are
based on present circumstances and on management’s present beliefs
with respect to events that have not occurred, that may not occur,
or that may occur with different consequences or timing than those
now assumed or anticipated. Actual results may differ materially
from those expressed in forward looking statements due to
known and unknown risks and uncertainties, such as are not
guarantees of general economic and business conditions, the ability
to successfully develop and market products, consumer and business
consumption habits, the ability to consummate successful
acquisition and licensing transactions, fluctuations in exchange
rates, and other factors over which Tauriga has little or no
control. Many of these risks and uncertainties are discussed in
greater detail in the “Risk Factors” section of Tauriga’s Form 10-K
and other filings made from time to time with the Securities and
Exchange Commission. Such forward-looking statements are made only
as of the date of this release, and Tauriga assumes no obligation
to update forward-looking statements to reflect subsequent events
or circumstances. You should not place undue reliance on these
forward-looking statements.
Contact:
CONTACT INFORMATION
Tauriga Sciences, Inc.
555 Madison Avenue, 5th Floor
New York, NY 10022
Chief Executive Officer
Mr. Seth M. Shaw
Email: sshaw@tauriga.com
cell # (917) 796 9926
Corp. Website: www.tauriga.com
E-Commerce Website: www.taurigum.com
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Sep 2023 to Sep 2024